Clinical Trial Update: Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a combination of sintilimab, peg-aspargase, and anlotinib for Natural Killer/T-Cell Lymphoma (nasal/nasal-type) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasal-type Nk T-cell Lymphoma
• Natural Killer T-cell Lymphoma

Drugs mentioned

• Anlotinib (anlotinib)
• Peg-aspargase (peg-aspargase)
• Sintilimab (sintilimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, Early Stage | Phase 2 | Status: COMPLETED